Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Cancer Research|June 6, 2013
C-RAF mutations confer resistance to RAF inhibitorsRajee Antony, Caroline M Emery, Allison M Sawyer, et al.Molecular Cancer Research : MCR|June 29, 2017
BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic ActivityCaroline M Emery, Kelli-Ann Monaco, Ping Wang, et al.Proceedings of the National Academy of Sciences of the United States of America|November 17, 2009
MEK1 mutations confer resistance to MEK and B-RAF inhibitionCaroline M Emery, Krishna G Vijayendran, Marie C Zipser, et al.Molecular Cancer Therapeutics|September 24, 2017
Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)Ursula A Germann, Brinley F Furey, William Markland, et al.Plos One|September 18, 2015
Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor LineagesAnupama Reddy, Joseph D Growney, Nick S Wilson, et al.Cancer Discovery|December 17, 2017
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J Sullivan, Jeffrey R Infante, Filip Janku, et al.Plos One|November 20, 2009
Profiling critical cancer gene mutations in clinical tumor samplesLaura E MacConaill, Catarina D Campbell, Sarah M Kehoe, et al.Nature|November 26, 2010
COT drives resistance to RAF inhibition through MAP kinase pathway reactivationCory M Johannessen, Jesse S Boehm, So Young Kim, et al.Pageof 1